Can biotech, pharma and device companies devise an innovative response to the diabetes epidemic and profit at the same time? Stryker CEO Steve MacMillan, discusses the topic with CNBC.
COMMENTS
Thank you for joining our discussion. Your comment has been posted.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT